Skip to main content

Table 3 Baseline intake of medications in each cohort

From: Suboptimal cardiovascular risk factor identification and management in patients with rheumatoid arthritis: a cohort analysis

N =251/group   Group A (RA) Group B (DM) Group C (GP) P, all three P, A versus C
Medications       
RA MTX 126 (50%) N/A N/A -- --
  HCQ 92 (37%) N/A N/A -- --
  PDN 86 (34%) N/A N/A -- --
  TNF 96 (38%) N/A N/A -- --
DM Insulin N/A 100 (40%) N/A -- --
  Metformin N/A 132 (53%) N/A -- --
NSAIDs   74 (29%) 43 (17%) 51 (20%) 0.003 0.02
Anti-HTN   66 (26%) 180 (72%) 86 (34%) < 0.0001 0.052
Statin   23 (9%) 162 (65%) 38 (15%) < 0.0001 0.055
ASA 81 mg 22 (9%) 93 (37%) 33 (13%) < 0.0001 0.12
  > 81 mg 5 (2%) 16 (6%) 6 (2%) 0.01 0.76
  1. Anti-HTN, antihypertensives; ASA, aspirin; DM, diabetes mellitus; GP, general population; HCQ, hydroxychloroquine; LEF, leflunomide; MTX, methotrexate; N/A, not applicable; NSAIDs, nonsteroidal antiinflammatory drugs; PDN, prednisone; RA, rheumatoid arthritis; TNF, anti-TNF agents.